LIFE CHANGING
INVESTMENTS
ATEM Capital invests in innovations across the Life Sciences industry with the promise to cure once-incurable diseases that help people live longer. Our target technologies are breakthroughs with unmet clinical need, strong IP protection, and the appeal to become a must-have for strategic players. We completed many successful transactions with a superior return on invested capital in partnership with the leading US and EU venture groups.
LIFE CHANGING INVESTMENTS
ATEM Capital invests in innovations across the Life Sciences industry with the promise to cure once-incurable diseases that help people live longer. Our target technologies are breakthroughs with unmet clinical need, strong IP protection, and the appeal to become a must-have for strategic players. We completed many successful transactions with a superior return on invested capital in partnership with the leading US and EU venture groups.
ATEA Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.

Atea went public at a valuation of $1.9 billion which makes over 30x of our Series A investment back in 2014 at pre-money $10 million. The company made an exclusive partnership with Roche for the ex-US rights ahead of the IPO.
NEXT: Iridia
NASDAQ: AVIR, IPO in Oct 2020
Our Team Investments
Iridia
Iridia, a synthetic biology company backed by Western Digital and LifeSci Venture Partners, is developing the world's first commercially attractive, DNA-based data storage solution with a highly parallel format.

The company's technology enables an array of nanomodules with the potential to store data at exceptionally high density.
NEXT: Syndax Pharmaceuticals
Our Team Investments
Our Team Investments
Syndax Pharmaceuticals
Syndax is a clinical-stage biotech company developing an innovative pipeline of cancer therapies. The company’s CEO is Briggs W. Morrison, a managing director of MPM Capital and a former head of R&D at AstraZeneca. Syndax pipeline includes a highly selective inhibitor of the Menin–MLL binding interaction to treat acute leukemias, axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor against chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.
NEXT: Epic Sciences
NASDAQ: SNDX, IPO in Feb 2016
Our Team Investments
Epic Sciences
Epic Sciences developed susceptible tests that molecularly characterize circulating tumor cells in the blood to open up a new way to detect cancer and personalize/monitor treatments. Epic Sciences, an unbiased approach using the Comprehensive Cancer Profiling liquid biopsy platform, sees those rare cells that others miss. Epic gives cancer patients and their physicians the clear, accurate insights they need to choose the best course of therapy.
NEXT: Tobira Therapeutics
Our Team Investments
Tobira Therapeutics
Tobira developed cenicriviroc (CVC), a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a liver scarring disease that affects millions of people and is growing alongside the high rates of obesity and diabetes, but has no approved therapies.

In September 2016, Allergan acquired Tobira Therapeutics in a US$1.7 billion deal, or 19 times its previous market value.
NEXT: ATEA Pharmaceuticals
Our Team Investments
Our Team Investments
INVRSTOR FRIENDLY
FINANCIAL
VEHICLE
ATEM Capital invests in innovations across the Life Sciences industry with promise to cure once-incurable diseases that help people live longer. Our target technologies are breakthroughs with unmet clinical need, strong IP protection and the appeal to become a must-have for strategic players. We completed a lot of successful transactions with a superior return on invested capital in partnership with the leading US and EU venture groups.
Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.

Atea went public at a valuation of c.$1.9 billion which makes over 30x of
our Series A investment back in 2014 at $10 million. The company made an exclusive partnership with Roche for the ex-US rights ahead of the IPO.
ATEA Pharmaceuticals
Our Team Investments
VISIT
NASDAQ: AVIR, MC $6.9B
IPO in Oct 2020
NEXT: Iridia
WHY
HEALTHCARE?
Fundamental factors are fueling steady growth of the healthcare markets worldwide despite any financial vulnerabilities, with latest years setting a new sustainable record. Government and people spend on healthcare is constantly increasing both in absolute and relative terms notwithstanding financial vulnerabilities, thus creating stable multi-billion markets and second to none investment opportunities
Download ATEM’s Life Sciences industry report to learn more about healthcare's accommodative liquidity and bulletproof fundamentals
OUR GAME-CHANGING
STRATEGY
Get the efficient access to one of the most exciting and private asset class of Life Sciences innovations
Landmark deal flow
of major like-minded US and Western Europe VC firms as well as exclusive private projects of successful serial entrepreneurs
Real-time insights
from most connected Advisory Board into investment opportunities and emerging Big Pharma needs
Industrial-quality diligence
to optimize decision-making process and risk management
INVEST IN
CURES
ATEM acts in a strategic partnership with the largest US and EU Venture Firms, and possesses critical mass, topnotch expertise, industrial quality diligence and professional board level control to identify superior technologies with strong IP protection and provide healthy returns to investors
INVESTNENT
THEMES
30% — Scientific Home-Runs
Early-stage breakthrough science managed by high-caliber serial entrepreneurs with unmatched track-record of success
40% — Next Gen Bioplatforms
Fast-growing biopharma companies with diversified and robust pipeline and sound promise to go public or ready for M&A within one to three years
30% — Medicine Automation
Post-revenue companies in AI drug discovery, alternative care, digital therapeutics and robotics with potential for multibillion growth
BECOME A PART OF THE NEXT
SCIENTIFIC BREAKTHROUGH
IMMUNO-ONCOLOGY
Projects with cure ambition,
novel MoA, use of innovative
delivery platforms, and signs of efficacy
AUTOIMMUNE DISEASES
Technologies saving lives with
strong preclinical and clinical data and manageable regulatory path
RARE DISEASES
Customizable therapeutics for people with genetic diseases that have no treatment or cure
NEUROLOGY
Projects that let people enjoy their life experiences, with human proof-of concept, understood mechanism of action and clear regulatory path
Invest with us
OUR
LEADERSHIP
Our international team combines big
picture perspective and long-term
technology view with decades of diverse
experience in investments, scientific research, clinical development, IP and operations

Тeam
Anton GOPKA
General Partner
Elena MALIC
General Partner
Zachar LEYKIN, M.D.
Medical Advisor
Peter STAROKADOMSKY
Scientific Advisor
Yulii BOGATYRENKO
Venture Partner
Viktor KOTELIANSKY, PhD
Medical Partner
KNOWLEDGE
CENTER
Yahoo!Finance
Mar. 16, 2021
Oversubscribed Financing to Build World’s First High-Density DNA-Based Memory Chip
ATEM Capital backs Iridia, a pioneer in fully integrated DNA-based memory chips, in its oversubscribed Series B financing led by LifeSci Venture Partners and Western Digital

VISIT
BIOPHARMA DIVE
Oct. 30, 2020
Atea, riding interest in COVID-19 drugs, pulls off one of 2020's top biotech IPOs
Boston biotech Atea Pharmaceuticals, a developer of small molecule drugs for infectious diseases, has raised $300 million in an upsized initial public offering. Atea's IPO was the fourth largest U.S. biotech stock offering of 2020 and the eighth biggest since the start of 2018.

VISIT
MarketWatch
Apr. 20, 2021
Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias.

VISIT
ATEM acts in a strategic partnership with the largest US and EU Venture Firms, and possesses critical mass, topnotch expertise, industrial quality diligence and professional board level control to identify superior technologies with strong IP protection and provide healthy returns to investors
Invest with us
GET IN TOUCH
Made on
Tilda